- Funded iBio’s Phase I clinical trial of H1N1 influenza vaccine
- Over $30 million in non-dilutive funding
iBio establishes partnerships through product collaborations and platform licensing arrangements.
The iBio Technology has been validated across a wide range of applications in both vaccines and biotherapeutics, and these products are available for license along with the technology to bring innovative medicines to patients.
Out-licensing products produced with the iBio Technology platform
Partnering iBio™'s technology for exploratory, research or validation studies
Out-licensing the iBio Technology platform for the production of biotherapeutics and vaccines
iBio's business strategy is to broadly participate in the markets that the iBio Technology platform addresses.
Current partner projects include:
We're delighted to form this new global alliance with iBio, who share our vision of bringing affordable and flexible manufacturing capabilities to the producers of these vital, lifesaving medicines.
We look forward to continuing our work with the talented teams at iBio and CMB to explore how this innovative technology could become a commercial reality.
iBio is establishing partnerships through iBio Technology platform licensing arrangements and product collaborations.Interested in Becoming a Partner?
The iBio Technology platform is a proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins and has been validated across a wide range of applications in both vaccines and biotherapeutics.Learn more